Market revenue for the North America U.S. IVD sector shows robust growth between 2020 and 2035. Starting around USD 16,700 Million in 2020, revenues are projected to increase steadily with a CAGR of around 6.2%, reaching approximately USD 47,800 Million by 2035. Expansion is fueled by the growing burden of chronic diseases, technological evolution in diagnostics, and proactive healthcare infrastructure investments across the region. The U.S. maintains leadership, with Canada and Mexico exhibiting promising growth trends.

Read More - https://bussinessinsights.com/research-report/north-america-u.s.-in-vitro-diagnostics-(ivd)-market

By application, infectious diseases represent the largest share of the North America U.S. IVD market in 2025 due to a persistent need for fast, accurate diagnostics in light of global health threats like COVID-19 and emerging pathogens. Diabetes and oncology applications are also significant contributors, reflecting rising prevalence and prioritization of early detection in clinical protocols. Enhanced focus on population health management and personalized medicine further propels demand for robust diagnostic assays.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-u.s.-in-vitro-diagnostics-(ivd)-market

Frequently Asked Questions

Who are the key players in North America U.S. In Vitro Diagnostics (IVD) Market industry?
The top 5 key players in the North America U.S. IVD Market are Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Becton Dickinson (BD), and Siemens Healthineers. These companies lead the market through innovative diagnostic solutions, extensive product portfolios, and strategic partnerships, driving advancements in diagnostic technologies.

What is the North America U.S. In Vitro Diagnostics (IVD) Market growth?
The North America U.S. IVD market has witnessed steady growth, with an estimated CAGR of around 5-7% from 2021 to 2024. Recent growth factors include increased adoption of molecular diagnostics and point-of-care testing, with Abbott expanding its rapid COVID-19 and flu testing platforms in 2023.

Which segment accounted for the largest North America U.S. In Vitro Diagnostics (IVD) Market share?
The molecular diagnostics segment accounted for the largest market share in the U.S. IVD market. Its dominance is driven by rising demand for PCR and genetic testing for infectious diseases and oncology, supported by advancements from companies like Roche Diagnostics and Thermo Fisher Scientific.

Thanks & Regards,
Priya
sales@bussinessinsights.com